Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340141 · ClinicalTrials.gov registry record · Phase 3
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
A Phase 3 study of Pancreatic Cancer and Resectable Pancreatic Adenocarcinoma, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 358
- Enrollment target
- 20
- Study locations
NCT04340141 is a Phase 3 study of Pancreatic Cancer and Resectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 358 participants, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT04340141, a Phase 3 study of Pancreatic Cancer and Resectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 358 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Irinotecan Hydrochloride
- PROCEDURE Resection
- DRUG Leucovorin Calcium
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Thomas Hospital - Fairhope
- Mobile Infirmary Medical Center - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Kaiser Permanente-Bellflower - Bellflower
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
Arizona
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2030-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340141
The ClinicalTrials.gov registry entry for NCT04340141 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT04340141 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alaska, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04340141 about?
NCT04340141 is a clinical study titled "Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer". This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin,...
What is the current status of trial NCT04340141?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2020-10-13. Estimated completion is 2030-11-01.
What conditions does trial NCT04340141 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma.
What interventions are being tested in trial NCT04340141?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Irinotecan Hydrochloride (DRUG), Resection (PROCEDURE), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT04340141?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04340141 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.